Ebola vaccine cuts death risk for people with past infections

Ervebo, Merck’s Ebola vaccine, reduced the fatality risk among patients who previously contracted the rare disease that kills 50% of those affected, according to new research

Advertisement

In a review of more than 2,000 people with confirmed Ebola cases in the Democratic Republic of Congo, researchers found case fatality was 27% among Ervebo patients and 56% among unvaccinated patients. The findings were published Feb. 7 in The Lancet Infectious Diseases.

The study is the first to research the retrospective efficacy of the Ebola vaccine, the researchers said.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.